-Partnership agreements will further diversify Lotus revenue base and create partnerships with leading global pharma companies
Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) today announced that it has made 10 new strategic partnership agreements in 2020 with some of the world’s leading pharmaceutical companies. The regions covered by these partnerships include the European Union, Middle East and North Africa (MENA), South Africa, Israel, Canada, Brazil and Columbia.
otus will be responsible for the development, regulatory affairs and manufacturing of the products for its partners that include Lenalidomide, Sunitinib, Enzalutamide. Recent partnership agreements have also been made for products still under development coming from Lotus’ leading oncology portfolio.
Petar Vazharov, Chief Executive Officer of Lotus, commented: “We are pleased to have been able to strike agreements with these leading pharmaceutical companies. In doing so, we are diversifying our revenue base outside the APAC region and positioning Lotus as a global leader in oncology medicines and complex generics. The partnerships will also benefit patients around the world, which now may have better access to high quality medicines. The series of agreements are the product of a hard-working B2B team which is driven by the pursuit of delivering profitable growth, which can be reinvested in R&D, high-quality manufacturing, services and partnerships.”